West Nadja sold $532K of THC

West Nadja sold 3,000 shares of TENET HEALTHCARE CORP (THC) at $177.35 ($0.53M total) on 2026-05-27.

Original reporting
SEC EDGAR · West Nadja
Published May 28, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$THC
Neutral
medium confidence
Mentioned
$THC
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

The newest disclosed fact is the sale size, price, and post-transaction holdings. It does not include any operational, financial, or regulatory development for the issuer.

02

Market read

Traders may note the sale for sentiment, but there is no fundamental catalyst in the text.

03

What to watch

Insider sales can be driven by diversification, taxes, or personal liquidity needs; without additional context, the signal-to-noise is low.

Relevance 5/10Novelty 3/10Timing: SEC Form 4 filed 2026-05-28, covering sale dated 2026-05-27

Background

The article is an SEC Form 4 insider transaction disclosure for Tenet Healthcare Corp, reported by director West Nadja.

Company-level read

Ticker impact

$THCNeutralMedium confidence
Context

Tenet Healthcare director West Nadja sold 3,000 shares at $177.35 via an open-market sale, disclosing holdings after the trade.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-only and typically fades.

Evidence & confidence

The filing is an open-market sale, not a buy, and it explicitly states no pre-arranged 10b5-1 plan, but the article provides no accompanying corporate or guidance catalyst.

Market effects

No sector-level implications; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Absence of a 10b5-1 plan could be interpreted by some traders as less mechanical selling, potentially increasing short-term scrutiny.

Key entities

  • Tenet Healthcare Corp

    Company whose director insider sale is disclosed on Form 4.

  • West Nadja

    Director who sold 3,000 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

$THCHighAI 8/10

Mizuho raises Tenet Healthcare stock price target on strong results

Mizuho increased its price target for Tenet Healthcare (NYSE:THC) to $305 from $290, citing strong quarterly results and raised 2026 EBITDA estimates. The stock trades near its 52-week high after a 49% six-month surge. Tenet reported Q3 2026 EPS of $6.64, beating estimates, and raised its full-year EBITDA outlook. Guggenheim maintained a Buy rating with a slightly lowered target of $306.

$THCMed

Tenet Healthcare Q3 Earnings Call Highlights

Tenet Healthcare (THC) reported Q3 earnings, with hospital segment showing 3.2% growth in admissions and 11% adjusted EBITDA increase. Revenue per admission rose 0.2% YoY. Exchange admissions and revenues declined 18%. Conifer transition activities contributed $147M, with $450M expected in 2026. Tenet generated $1.1B in adjusted free cash flow and repurchased 970K shares.